Riskpilot← Back to searchSign inGet full accessAVILEX PHARMA ApS
APSActiveCVR 34896828Ole Maaløes Vej 3Research and experimental development on natural sciences and engineering · NACE 7210Est. 20124 employeeshttp://www.avilexpharma.com
Revenue 2024
—
EBITDA margin
—
+20% vs 2023
Equity ratio
-29.1%
Financial strength
Net profit 2024
DKK -4,4M
+34% vs 2023
| Revenue | — | — |
| EBITDA | DKK -4,8M | +20% |
| Net profit | DKK -4,4M | +34% |
| Total assets | DKK 21,6M | -23% |
| Equity | DKK -6,3M | -241% |
| Employees | 4 | — |
Legal name
AVILEX PHARMA ApS
CVR number
34896828
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
27. december 2012
Share capital
DKK 469.198
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden, eller af to bestyrelsesmedlemmer i forening, eller af bestyrelsesformanden i forening med et andet bestyrelsesmedlem.
Company purpose
Selskabets formål er udvikling af behandlingsmæssige peptider eller afledte peptider (monomer, dimer og trimer) eller små molekylære forbindelser som er rettet mod PDZ domæner og relateret virksomhed besluttet af bestyrelsen.
Address
Ole Maaløes Vej 3
Website
http://www.avilexpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | -3.133 | — | 45.479 | 0 | — |
| Staff expenses | -326 | -0 | -1.096 | -1.909 | -725 | -975 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -3.178 | -836 | -7.337 | -6.825 | -3.514 | -4.420 | -4.092 | -3.133 | -8.684 | 34.858 | -6.034 | -4.803 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -3.178 | -836 | -7.337 | -6.825 | -3.514 | -4.420 | -4.092 | -3.133 | -8.684 | 34.858 | -6.034 | -4.803 |
| Net financials | -357 | -389 | -234 | -161 | -266 | -524 | -689 | -845 | -942 | 1.803 | -2.666 | 68 |
| Profit before tax | -3.536 | -1.469 | -9.843 | -6.986 | -3.780 | -4.944 | -4.780 | -3.978 | -9.626 | 36.661 | -8.700 | -4.735 |
| Tax | -587 | -0 | -0 | -1.535 | -1.364 | -1.084 | -1.054 | -936 | -3.015 | 8.061 | -1.944 | -307 |
| Net profit | -2.949 | -1.224 | -7.571 | -5.451 | -2.416 | -3.861 | -3.726 | -3.042 | -6.611 | 28.600 | -6.756 | -4.428 |
| Item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 2.195 | 1.272 | 10.412 | 4.780 | 7.253 | 6.749 | 9.444 | 9.375 | 4.917 | 31.591 | 27.875 | 21.559 |
| Equity | -2.869 | -4.093 | -279 | -5.730 | -8.146 | -11.881 | -15.608 | -18.649 | -25.260 | 4.917 | -1.839 | -6.267 |
| Long-term debt | 4.858 | 0 | 9.660 | 9.863 | 14.586 | 18.096 | 24.744 | 25.584 | 27.399 | 24.283 | 26.935 | 23.829 |
| Short-term debt | 206 | 5.365 | 1.031 | 647 | 812 | 534 | 308 | 2.440 | 2.778 | 2.391 | 2.779 | 3.997 |
| Total debt | 5.064 | 5.365 | 10.691 | 10.510 | 15.398 | 18.630 | 25.052 | 28.024 | 30.177 | 26.674 | 29.714 | 27.826 |
EBITDA margin
-480300000.0%
This company
15.8%
Market median
-3039873518% vs market
20132024
Equity ratio
-29.1%
This company
38.2%
Market median
-176% vs market
20132024
Return on equity
-442800000.0%
This company
18.4%
Market median
-2406521839% vs market
20132024
Net profit margin
-442800000.0%
This company
8.1%
Market median
-5466666767% vs market
20132024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20132024
Debt / equity
4.44×
This company
0.62×
Market median
-616% vs market
20132024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2012-12-27 – 2013-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NL Management | Management | 2013 | — | — |
KS Management | Management | 2016 | — | — |
RG Chief Executive Officer | Chief Executive Officer | 2013 | — | — |
AB Founder | Founder | 2012 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2014 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2015 | — | — | |
| Chairman | 2013 | — | — | |
| Board of Directors | 2018 | — | — | |
| Chairman | 2016 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2014 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Novo Holdings A/S | Company | 50.0% | 50.0% | 2022 |
KRISTIAN STRØMGAARD HOLDING ApS | Company | 20.0% | 20.0% | 2019 |
Anders Bach ApS | Company | 10.0% | 10.0% | 2019 |
MIKAEL SØNDERGÅRD THOMSEN ApS | Company | 5.0% | 5.0% | 2019 |
| Individual | 5.0% | 5.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NOVO NORDISK FONDEN
AVILEX PHARMA ApS Board members of AVILEX PHARMA ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nanna Liebach Lüneborg | Management | 0 companies |
| Kristian Strømgaard | Management | 0 companies |
| Robert Giles Tansley | Chief Executive Officer | 0 companies |
| Anders Bach | Founder | 0 companies |
| Bobby G Soni | Chairman | 0 companies |
| Morten Døssing | Board of Directors | 0 companies |
| Emmanuelle Coutanceau | Chairman | 0 companies |
| Ingelise Saunders | Chairman | 0 companies |
| Jonathan Mark Treherne | Board of Directors | 0 companies |
| Raymond George Hill | Chairman | 0 companies |
| Camilla Petrycer Hansen | Board of Directors | 0 companies |
| Henrijette Elsebeth Richter | Chairman | 0 companies |